Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2018-11-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于全资子公司通过高新技术企业认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (654 characters) regarding a subsidiary company passing a high-tech enterprise certification and the related tax benefits. It does not contain financial statements, detailed financial data, or management discussion. It is an official company announcement about a regulatory or operational update, not a report or detailed filing. It is not a report publication announcement since it does not mention any report being published or attached. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-11-19 Chinese
关于注射用重组人生长激素新增适应症申请的进展公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the progress of a new indication application for a drug (recombinant human growth hormone). It references regulatory approval from the National Medical Products Administration for clinical trials of new indications. The document is short (854 characters) and primarily provides an update on regulatory approval and clinical trial status, without any financial data or detailed financial reporting. It is not an annual report, earnings release, or any detailed financial or management report. It is also not a voting result, board change, or capital update. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about drug approval progress and clinical trial permissions, which does not fit other specific categories.
2018-11-16 Chinese
关于第二期限制性股票激励计划部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Anhui Anke Biotechnology (Group) Co., Ltd. regarding the completion of a repurchase and cancellation of restricted shares under the company's second restricted stock incentive plan. It details the number of shares repurchased, pricing basis, board approvals, and changes in share capital structure. The content focuses on share repurchase and cancellation activities related to stock incentives, including specific share quantities, prices, and dates. There is no indication of financial statements, earnings data, or management discussion of financial results. The document is not a full financial report but an announcement of a share repurchase and cancellation event. Therefore, it fits best under the category of Transaction in Own Shares (POS).
2018-11-13 Chinese
关于非公开发行股票申请获得中国证监会核准的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the approval by the China Securities Regulatory Commission (CSRC) for a non-public issuance of shares. It details the approval of issuing up to 99,747,396 new shares, the validity period of the approval, and the company's commitment to comply with regulations and disclose information timely. The content focuses on a capital raising activity through a non-public stock issuance, which aligns with updates on company financing activities or capital structure changes. The document is relatively short (944 characters) and is a formal announcement of the approval, not a detailed report or financial statement. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-11-09 Chinese
2018年第三季度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (332 characters) indicating that the full 2018 third quarter report (interim report) has been published on the official disclosure website. It does not contain the actual financial data or substantive analysis itself, but merely informs investors where to find the full report. According to the 'Menu vs Meal' rule, such a brief notice pointing to the full report is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2018-10-29 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding a change in accounting policies. It references a specific regulatory notice (财会[2018]15号) issued by the Ministry of Finance of China, which mandates changes in the financial statement formats. The document details the nature of the accounting policy changes, their impact on financial statement line items, and includes opinions from the board, independent directors, and the supervisory board. The document is relatively short (2631 characters) and does not contain actual financial statements or detailed financial data. Instead, it serves as a formal announcement of the accounting policy change and related approvals. It is not a full annual or interim report, nor an audit report or earnings release. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-10-29 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.